Free CME from PeerView


Gynecology/Obstetrics CME

Credits: 1.0 CME / MOC / CPE
Medical Learning Institute, Inc.
Making Sense of the Evolving Treatment Landscape in Ovarian Cancer Care: Pharmacy Perspectives on PARP Inhibitor Therapy
Thomasina Morris, RPh, MHA, BCOP
May 06, 2022
Credits: 1.0 CME / MOC / CC / NCPD / CPE
Medical Learning Institute, Inc.
How to Harness Adjuvant CDK4 and 6 Inhibition to Prevent Recurrences in High-Risk HR+/HER2- Early Breast Cancer: New Goals and Better Tools to Close the Gaps
Erika Hamilton, MD
April 29, 2022
Credits: 0.5 CME / MOC / NCPD
Medical Learning Institute, Inc.
Expanding the Benefits and Refining the Role of Immune Checkpoint Inhibitors in the Treatment of Recurrent and Advanced Endometrial Cancer
Bhavana Pothuri, MD, MS
April 27, 2022
Kristina M. Deligiannidis, MD
Credits: 1.0 CME
Medical Learning Institute, Inc.
Applying Evidence to Practice in Postpartum Depression: Expert Guidance on Integrating Therapeutic Innovations and Shared Decision-Making Strategies to Optimize Patient Care
Kristina M. Deligiannidis, MD
April 09, 2022
Credits: 1.25 CME
Medical Learning Institute, Inc.
Expanding the Benefits of PARP Inhibitor Therapy to More Patients With Breast Cancer and Earlier Disease Settings: Multidisciplinary Perspectives on How to Maximize the Potential of PARP Inhibitors and Optimize Their Use as Part of Multimodal Management o
Henry M. Kuerer, MD, PhD, FACS
April 08, 2022
Credits: 1.0 CME / MOC
PVI, PeerView Institute for Medical Education
Cancer Screening and Preventive Care for Transgender Individuals: Patient and Provider Perspectives on Best Practices and Special Considerations
Elizabeth Eaman, MD
April 01, 2022
Credits: 0.5 CME
Medical Learning Institute, Inc.
Recent Advances in the Management of Depressive Disorders: Preparing for a Shift in the Treatment Paradigm
Anita H. Clayton, MD
March 31, 2022
Credits: 1.5 CME / MOC / CC
Medical Learning Institute, Inc.
Decoding the Latest Evidence and Practical Recommendations on Biomarker Testing for New Therapeutic Options Targeting HER2, HER3, and TROP2 in Solid Tumors
Kurt A. Schalper, MD, PhD
March 23, 2022
Credits: 1.0 CME / MOC / NCPD
Medical Learning Institute, Inc.
When Are PARP Inhibitors the Best Choice for Patients With Ovarian Cancer? Personalizing Therapeutic Selection Across the Disease Continuum
Bradley J. Monk, MD, FACS, FACOG
March 22, 2022
Henry M. Kuerer, MD, PhD, FACs / Heather L. McArthur, MD, MPH
Credits: 1.0 CME / MOC
PVI, PeerView Institute for Medical Education
Translating Progress With Immunotherapies and Targeted Agents Into Improved Outcomes in Triple-Negative Breast Cancer: Surgical and Clinical Perspectives on Modern Multimodal Treatment Approaches
Henry M. Kuerer, MD, PhD, FACs / Heather L. McArthur, MD, MPH
March 12, 2022
Credits: 0.5 CME
PVI, PeerView Institute for Medical Education
Putting the Pieces Together: Would You Recognize Acute Hepatic Porphyria If You Saw It?
Herbert L. Bonkovsky, MD
February 25, 2022
Erika Hamilton, MD
Credits: 1.0 CME
Medical Learning Institute, Inc.
Expanding Treatment Options in ER+/HER2- Breast Cancer: Expert Perspectives on the Rapidly Emerging Role of SERDs, SERMs, and SERCAs, and the Practical Considerations of Leveraging Established and Innovative Therapies
Erika Hamilton, MD
January 19, 2022
Credits: 1.5 CME / MOC / NCPD
Medical Learning Institute, Inc.
Personalizing Treatment Decisions in HER2-Altered Breast Cancer: Strategies for Improving Equity and Patient Outcomes Through Individualized Targeted Therapy Selection, Team-Based Care, and Shared Decision-Making
Joyce O’Shaughnessy, MD
December 10, 2021
Credits: 0.5 CME / MOC / NCPD
PVI, PeerView Institute for Medical Education
Changing Tides in Advanced Endometrial Cancer: A Visual Exploration of Current and Emerging Strategies to Maximize the Potential of Cancer Immunotherapies
Jubilee Brown, MD
November 30, 2021
Richard Elion, MD / Rupa R. Patel, MD, MPH, DTM&H
Credits: 0.5 CME / MOC / NCPD / CPE
PVI, PeerView Institute for Medical Education
PrEP for All Ages: A Comprehensive Look at Employing HIV Prevention Strategies Across All Age Groups
Richard Elion, MD / Rupa R. Patel, MD / MPH, DTM&H
November 18, 2021
Donna E. Sweet, MD, AAHIVS, MACP
Credits: 0.75 CME / MOC / NCPD / CPE
Medical Learning Institute, Inc.
The HIV Prevention–Certified Provider Program: A Training and Certificate Program Designed to Improve Competencies and Expand the HIV Prevention Workforce
Donna E. Sweet, MD, AAHIVS, MACP
November 12, 2021
Credits: 1 CME / MOC / CC / NCPD / CPE
Medical Learning Institute, Inc.
Raising the Bar in HR+/HER2- Early Breast Cancer: Multidisciplinary Strategies for Integrating the CDK4 and 6 Inhibitors
Joyce O’Shaughnessy, MD
November 08, 2021
Credits: 1.5 CME / MOC / CC
Medical Learning Institute, Inc.
Evolving Standards in Biomarker Testing, Scoring, and Results Interpretation Driven by the Broadening Role of Cancer Immunotherapy
Kurt A. Schalper, MD, PhD
September 29, 2021
Credits: 1.50 CME / MOC
Medical Learning Institute, Inc.
Evaluating the Evidence and Parsing the Practicalities of Therapeutic Choices in Advanced and Early HR+ Breast Cancer: Expert Perspectives on CDK4 and 6 Inhibitors and Other Novel Agents
Sara M. Tolaney, MD, MPH
July 07, 2021
Credits: 1.50 CME / MOC / NCPD
Medical Learning Institute, Inc.
The Expanding Advanced Ovarian Cancer Treatment Palette: Candid Conversations on Bringing PARP Inhibitors Into Clinical Practice
Deborah K. Armstrong, MD
July 06, 2021
Credits: 1.50 CME / MOC / CC
Medical Learning Institute, Inc.
Expanding the Benefits of Checkpoint Inhibitors and Targeted Agents in the Treatment Arsenal for Triple-Negative Breast Cancer
Joyce O’Shaughnessy, MD
July 02, 2021
Credits: 1.5 CME / MOC / NCPD
Medical Learning Institute, Inc.
Making Progress in Early and Advanced HER2-Positive Breast Cancer: Leveraging HER2-Targeted Therapies and Modern Care Principles to Improve Clinical Outcomes and Health Equity
Sara Hurvitz, MD
July 02, 2021
Credits: 0.75 CME / MOC / NCPD
Medical Learning Institute, Inc.
Navigating Shifts in the Treatment Landscape for Metastatic HER2-Positive Breast Cancer: Can New HER2-Targeted Therapies Address Unmet Needs and Offer Better Options for Challenging Patient Populations?
Shanu Modi, MD
June 01, 2021
Purdue University College of Pharmacy
Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice
Evan J. Lipson, MD
May 11, 2021
Medical Learning Institute, Inc.
Enhancing Personalized Medicine in Advanced Ovarian Cancer: Expert Guidance on Integrating the Latest Updates on PARP Inhibitors and Novel Therapeutic Innovations Into Your Clinical Practice
May 11, 2021
Medical Learning Institute, Inc.
Target Practice: Understanding How PARP Inhibitors Take Aim at DNA Damage Response Mutations Across Solid Tumors
Susana Banerjee, MBBS, MA, FRCP, PhD
May 07, 2021
Medical Learning Institute, Inc.
Acute Hepatic Porphyria: Disease Diagnosis and Revelations Regarding the Role of siRNA Therapy
Karl E. Anderson, MD
April 15, 2021
Medical Learning Institute, Inc.
HER2 and HER3 Alterations as Therapeutic Targets of Increasing Significance in Solid Tumors: Implications for Pathology and Oncology Practice
Kurt A. Schalper, MD, PhD
April 06, 2021
Hossein Borghaei, DO, MS / Sanjay Mukhopadhyay, MD
Medical Learning Institute, Inc.
The Nuances of Immunotherapy Biomarker Testing in Solid Tumors: Unraveling Complexities and Overcoming Challenges to Improve Outcomes
Hossein Borghaei, DO, MS / Sanjay Mukhopadhyay, MD
April 05, 2021
Medical Learning Institute, Inc.
Rewriting the Rules for Early Cancer Screening: Case-Based Insight on Primary Care Principles for Using Blood-Based Screening Techniques
John J. Russell, MD
March 25, 2021

Pages

Upcoming Live Events

Education Collections

Recent CME Podcast

More Podcasts from PeerView